In another signal of the appetite among investors for companies applying artificial intelligence to drug discovery, Pathos AI has gathered an impressive $365 million in fourth-round financing as it ...

The Velvet Underground and Rowan is the work of Londoners Leo Fincham, a visual artist and producer who records as Worldpeace ...

Spare yet tender, Gokhale’s prose carries an uncommon precision. She is attentive to the subtle shifts in human emotion and ...

If you want to get at the roots of contemporary advertising, you may need to go back about 2,000 years. It was Aristotle who first coined the three artistic proofs that are at heart of rhetoric and ...

(Alliance News) - Pathos Communications PLC on Wednesday said it expects a market capitalisation of GBP20.0 million on admission to London's AIM, as it confirmed the expected admission date is on ...

Born in California in 1902, John Steinbeck was ideally placed to document the American experience during one of the country’s most tumultuous periods. A person of German, English, and Irish descent, ...

TBC - website address containing all information required by AIM Rule 26 will be confirmed in due course and be made live on admission Pathos is a technology-enabled ...

From infomercials to political canvassing to appeals for coveted roles, the most compelling rhetoric uses a mix of ethos, pathos, and logos. These techniques encompass a wide spectrum of human ...

Gary Shteyngart was just seven years old when his family emigrated from the Soviet Union and settled in Queens. He remembers the transition as one of “leaving black-and-white for pure Technicolor.” ...

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI, the biotech drug developer spun out of Tempus ...

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. The ...